Summary
Global Market Direct’s pharmaceuticals report, “Angiotech Pharmaceuticals - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.
Scope
- Angiotech Pharmaceuticals - company overview including business description, key employees, and other facts.
- Review of current pipeline of Angiotech Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Angiotech Pharmaceuticals with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Angiotech Pharmaceuticals’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Angiotech Pharmaceuticals’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Angiotech Pharmaceuticals in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Angiotech Pharmaceuticals’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Angiotech Pharmaceuticals.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Angiotech Pharmaceuticals and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
Global Market Direct’s pharmaceuticals report, “Angiotech Pharmaceuticals - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.
Scope
- Angiotech Pharmaceuticals - company overview including business description, key employees, and other facts.
- Review of current pipeline of Angiotech Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Angiotech Pharmaceuticals with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Angiotech Pharmaceuticals’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Angiotech Pharmaceuticals’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Angiotech Pharmaceuticals in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Angiotech Pharmaceuticals’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Angiotech Pharmaceuticals.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Angiotech Pharmaceuticals and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 list of Figures
2 INTRODUCTION
3 ANGIOTECH PHARMACEUTICALS SNAPSHOT
3.1 Business Description
4 ANGIOTECH PHARMACEUTICALS- RESEARCH AND DEVELOPMENT OVERVIEW
4.1 Key Therapeutic Areas
5 ANGIOTECH PHARMACEUTICALS- PIPELINE REVIEW
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 ANGIOTECH PHARMACEUTICALS PIPELINE PRODUCTS GLANCE
6.1 Angiotech Pharmaceuticals Phase II Pipeline
6.2 Angiotech Pharmaceuticals Phase I Pipeline
6.3 Angiotech Pharmaceuticals Pre-Clinical Pipeline
7 ANGIOTECH PHARMACEUTICALS - DRUG PROFILES
7.1 Product
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 ANGIOTECH PHARMACEUTICALS PIPELINE ANALYSIS
8.1 Angiotech Pharmaceuticals Pipeline Products by Therapeutic Class
8.2 Angiotech Pharmaceuticals Pipeline Products by Target
8.3 Angiotech Pharmaceuticals Pipeline by Route of Administration
8.4 Angiotech Pharmaceuticals Pipeline Products by Molecule Type
9 ANGIOTECH PHARMACEUTICALS- RECENT PIPELINE UPDATES
10 ANGIOTECH PHARMACEUTICALS- DORMANT PIPELINE PROJECTS
10.1 Feature on Dormant Projects
11 ANGIOTECH PHARMACEUTICALS- DISCONTINUED PIPELINE PRODUCTS
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product
12 ANGIOTECH PHARMACEUTICALS – FEATURED NEWS
13 ANGIOTECH PHARMACEUTICALS STATEMENT
13.1 Angiotech Pharmaceuticals - Locations and Subsidiaries
14 APPENDIX
14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer
LIST OF TABLES
Table 1: Angiotech Pharmaceuticals - Key Information
Table 2: Angiotech Pharmaceuticals - Key Facts
Table 3: Angiotech Pharmaceuticals - Key Therapeutic Areas
Table 4: Angiotech Pharmaceuticals - Pipeline by Stage of Development,
Table 5: Angiotech Pharmaceuticals - Monotherapy Products in Pipeline,
Table 6: Angiotech Pharmaceuticals - Combination Treatment Modalities in Pipeline,
Table 7: Angiotech Pharmaceuticals - Phase II Pipeline,
Table 8: Angiotech Pharmaceuticals - Phase I Pipeline,
Table 9: Angiotech Pharmaceuticals - Pre-Clinical Pipeline,
Table 10: Angiotech Pharmaceuticals - Pipeline By Therapeutic Class
Table 11: Angiotech Pharmaceuticals - Pipeline By Target
Table 12: Angiotech Pharmaceuticals - Pipeline By Route of Administration
Table 13: Angiotech Pharmaceuticals - Pipeline By Molecule Type
Table 14: Angiotech Pharmaceuticals - Recent Pipeline Updates
Table 15: Angiotech Pharmaceuticals - Dormant Pipeline Projects
LIST OF FIGURES
Figure 1: Angiotech Pharmaceuticals - Research and Development Overview
Figure 2: Angiotech Pharmaceuticals - Pipeline by Stage of Development,
Figure 3: Angiotech Pharmaceuticals - Monotherapy Products in Pipeline,
Figure 4: Angiotech Pharmaceuticals - Combination Treatment Modalities in Pipeline,
Figure 5: Angiotech Pharmaceuticals - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Angiotech Pharmaceuticals - Pipeline By Therapeutic Class
Figure 7: Angiotech Pharmaceuticals - Pipeline By Target and Stage of Development
Figure 8: Angiotech Pharmaceuticals - Pipeline By Target
Figure 9: Angiotech Pharmaceuticals - Pipeline By Route of Administration and Stage of Development
Figure 10: Angiotech Pharmaceuticals - Pipeline By Route of Administration
Figure 11: Angiotech Pharmaceuticals - Pipeline By Molecule Type and Stage of Development
Figure 12: Angiotech Pharmaceuticals - Pipeline By Molecule Type
COMPANIES MENTIONED
Angiotech Pharmaceuticals
1.1 List of Tables
1.2 list of Figures
2 INTRODUCTION
3 ANGIOTECH PHARMACEUTICALS SNAPSHOT
3.1 Business Description
4 ANGIOTECH PHARMACEUTICALS- RESEARCH AND DEVELOPMENT OVERVIEW
4.1 Key Therapeutic Areas
5 ANGIOTECH PHARMACEUTICALS- PIPELINE REVIEW
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 ANGIOTECH PHARMACEUTICALS PIPELINE PRODUCTS GLANCE
6.1 Angiotech Pharmaceuticals Phase II Pipeline
6.2 Angiotech Pharmaceuticals Phase I Pipeline
6.3 Angiotech Pharmaceuticals Pre-Clinical Pipeline
7 ANGIOTECH PHARMACEUTICALS - DRUG PROFILES
7.1 Product
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 ANGIOTECH PHARMACEUTICALS PIPELINE ANALYSIS
8.1 Angiotech Pharmaceuticals Pipeline Products by Therapeutic Class
8.2 Angiotech Pharmaceuticals Pipeline Products by Target
8.3 Angiotech Pharmaceuticals Pipeline by Route of Administration
8.4 Angiotech Pharmaceuticals Pipeline Products by Molecule Type
9 ANGIOTECH PHARMACEUTICALS- RECENT PIPELINE UPDATES
10 ANGIOTECH PHARMACEUTICALS- DORMANT PIPELINE PROJECTS
10.1 Feature on Dormant Projects
11 ANGIOTECH PHARMACEUTICALS- DISCONTINUED PIPELINE PRODUCTS
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product
12 ANGIOTECH PHARMACEUTICALS – FEATURED NEWS
13 ANGIOTECH PHARMACEUTICALS STATEMENT
13.1 Angiotech Pharmaceuticals - Locations and Subsidiaries
14 APPENDIX
14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer
LIST OF TABLES
Table 1: Angiotech Pharmaceuticals - Key Information
Table 2: Angiotech Pharmaceuticals - Key Facts
Table 3: Angiotech Pharmaceuticals - Key Therapeutic Areas
Table 4: Angiotech Pharmaceuticals - Pipeline by Stage of Development,
Table 5: Angiotech Pharmaceuticals - Monotherapy Products in Pipeline,
Table 6: Angiotech Pharmaceuticals - Combination Treatment Modalities in Pipeline,
Table 7: Angiotech Pharmaceuticals - Phase II Pipeline,
Table 8: Angiotech Pharmaceuticals - Phase I Pipeline,
Table 9: Angiotech Pharmaceuticals - Pre-Clinical Pipeline,
Table 10: Angiotech Pharmaceuticals - Pipeline By Therapeutic Class
Table 11: Angiotech Pharmaceuticals - Pipeline By Target
Table 12: Angiotech Pharmaceuticals - Pipeline By Route of Administration
Table 13: Angiotech Pharmaceuticals - Pipeline By Molecule Type
Table 14: Angiotech Pharmaceuticals - Recent Pipeline Updates
Table 15: Angiotech Pharmaceuticals - Dormant Pipeline Projects
LIST OF FIGURES
Figure 1: Angiotech Pharmaceuticals - Research and Development Overview
Figure 2: Angiotech Pharmaceuticals - Pipeline by Stage of Development,
Figure 3: Angiotech Pharmaceuticals - Monotherapy Products in Pipeline,
Figure 4: Angiotech Pharmaceuticals - Combination Treatment Modalities in Pipeline,
Figure 5: Angiotech Pharmaceuticals - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Angiotech Pharmaceuticals - Pipeline By Therapeutic Class
Figure 7: Angiotech Pharmaceuticals - Pipeline By Target and Stage of Development
Figure 8: Angiotech Pharmaceuticals - Pipeline By Target
Figure 9: Angiotech Pharmaceuticals - Pipeline By Route of Administration and Stage of Development
Figure 10: Angiotech Pharmaceuticals - Pipeline By Route of Administration
Figure 11: Angiotech Pharmaceuticals - Pipeline By Molecule Type and Stage of Development
Figure 12: Angiotech Pharmaceuticals - Pipeline By Molecule Type
COMPANIES MENTIONED
Angiotech Pharmaceuticals